Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04181684 · ClinicalTrials.gov registry record · NA

LITT Followed by Hypofractionated RT for Recurrent Gliomas

A NA study of Glioblastoma and Neoplasms, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
NA
Development phase
32
Enrollment target
4
Study locations

NCT04181684 is a NA study of Glioblastoma and Neoplasms that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 32 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (71% lower). The trial reports 4 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04181684, a NA study of Glioblastoma and Neoplasms, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
NA
Development phase
32 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with recurrent gliomas.

Interventions

  • DEVICE Procedure: LITT
  • RADIATION Hypo-Fractionated Radiation Therapy

Study Locations (4)

Maryland

  • University of Maryland Greenebaum Cancer Center - Baltimore
  • UCH Kaufman Cancer Center - Bel Air
  • Central Maryland Radiation Oncology - Columbia
  • Baltimore Washington Medical Center - Glen Burnie

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2020-01-08
Est. Completion 2026-12
Phase NA

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT04181684

The ClinicalTrials.gov registry entry for NCT04181684 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (71% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Procedure: LITT is the first listed.

NCT04181684 reports 4 study locations spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04181684 about?

NCT04181684 is a clinical study titled "LITT Followed by Hypofractionated RT for Recurrent Gliomas". The purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with recurrent gliomas.

What is the current status of trial NCT04181684?

This trial is currently recruiting. It is a NA study. The enrollment target is 32 participants. The study started on 2020-01-08. Estimated completion is 2026-12.

What conditions does trial NCT04181684 study?

This clinical trial studies the following conditions: Glioblastoma, Neoplasms, Glioma, Brain Tumor.

What interventions are being tested in trial NCT04181684?

The interventions under investigation include: Procedure: LITT (DEVICE), Hypo-Fractionated Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT04181684?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04181684 being conducted?

This trial has 4 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.